Tuesday, May 25, 2021 6:58:39 PM
2021-05-25 06:53:41 PM ET (Reuters)
May 25 (Reuters) - Nabriva Therapeutics PLC:
* SINOVANT SCIENCES AND NABRIVA THERAPEUTICS ANNOUNCE POSITIVE TOPLINE RESULTS FROM PHASE 3 TRIAL OF LEFAMULIN IN CHINESE ADULTS WITH COMMUNITY ACQUIRED BACTERIAL PNEUMONIA (CABP)
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS GENERALLY SAFE AND WELL-TOLERATED IN CHINESE ADULTS
* NABRIVA THERAPEUTICS PLC - LEFAMULIN WAS SHOWN TO BE NON-INFERIOR TO MOXIFLOXACIN
* NABRIVA THERAPEUTICS PLC - GREATER CHINESE RIGHTS TO LEFAMULIN WILL BE HELD BY SUMITOMO PHARMACEUTICALS (SUZHOU) CO., LTD., Source text for Eikon: Further company coverage:
I use both Fundamental and Technical Analysis.
Opinions posted by me are just that, my opinion.
Buy/sell any type of financial security is the sole
decision of the individual. Make your own sound
judgement or consult a professional licensed
advisor.
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM